Conjunctival conveyance of SARS-CoV-2 in asymptomatic and non-severe symptomatic COVID-19 patients.

Conjonctive Conjunctiva Covid-19 Ocular surface SARS-CoV-2 Surface oculaire

Journal

Journal francais d'ophtalmologie
ISSN: 1773-0597
Titre abrégé: J Fr Ophtalmol
Pays: France
ID NLM: 7804128

Informations de publication

Date de publication:
Feb 2023
Historique:
received: 01 08 2022
accepted: 13 09 2022
pubmed: 13 1 2023
medline: 11 2 2023
entrez: 12 1 2023
Statut: ppublish

Résumé

The prevalence of ocular conveyance of SARS-CoV-2 has been well described for severe/hospitalized cases, but scarcely reported in asymptomatic and non-severe patients, who are unaware that they are carriers. This prospective cross-sectional study quantitatively evaluated SARS-CoV-2 shedding on the ocular surface (OS). Conjunctival testing was suggested to all hospital personnel being screened by nasopharyngeal (NP) SARS-CoV-2 reverse transcription polymerase chain reaction (RT-PCR). Disease symptoms were evaluated using a standardized questionnaire and telephone follow-up 6±3 months later for disease evolution (recovery with/without severe disease). Four hundred and eighty seven patients were included. From 46 NP SARS-CoV-2-positive subjects (cycle threshold [CT]=24.2±7.1), 13% tested positive at the OS (CT=36.4±2.8). Most SARS-CoV-2-positive subjects were symptomatic (n=40, 87%), while 6 were asymptomatic (being tested as contact cases). Systemic symptoms were not significantly different in OS-positive vs OS-negative subjects, although headache tended to be more frequent in OS-positives (83% vs 54%, P=0.06). None of the OS-positive subjects reported ocular symptoms and none developed severe disease requiring hospitalization or oxygen therapy. SARS-CoV-2 shedding at the OS may occur in asymptomatic and non-severe COVID-19 individuals (including those absent of ocular symptoms). However, the high RT-PCR CT values attained may indicate a low risk of transmissibility via this route.

Identifiants

pubmed: 36635207
pii: S0181-5512(23)00010-4
doi: 10.1016/j.jfo.2022.09.018
pmc: PMC9812824
pii:
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

101-105

Informations de copyright

Copyright © 2023 Elsevier Masson SAS. All rights reserved.

Auteurs

A Rousseau (A)

Department of Ophthalmology, Hôpital Bicêtre, Assistance Publique - Hôpitaux de Paris, Paris-Saclay University, French Reference network for rare Ophthalmologic diseases (OPHTARA), Le Kremlin-Bicêtre, France; Immunology of viral and autoimmune disease, IMVA, IDMIT, U1184, CEA, Fontenay aux Roses, France.

C Vauloup-Fellous (C)

Division of Virology, Dept of Biology Genetics and PUI, Paris-Saclay University Hospital, APHP, Villejuif, France; Inserm U1193, Université Paris-Saclay, Villejuif, France.

O Haigh (O)

Immunology of viral and autoimmune disease, IMVA, IDMIT, U1184, CEA, Fontenay aux Roses, France.

S Pavy (S)

Department of Rheumatology, Hôpital Bicêtre, Assistance Publique - Hôpitaux de Paris, Paris-Saclay University, Le Kremlin-Bicêtre, France.

D Molinari (D)

Clinical Research Unit, Hôpital Bicêtre, Assistance Publique - Hôpitaux de Paris, Paris-Saclay University, Le Kremlin-Bicêtre, France.

S Jauréguiberry (S)

Department of Infectious and tropical diseases, Hôpital Bicêtre, Assistance Publique - Hôpitaux de Paris, Paris-Saclay University, Le Kremlin-Bicêtre, France; Université de Paris Saclay, INSERM, CESP (Centre de Recherche en Epidémiologie et Santé des Populations), Villejuif, France.

A Angoulvant (A)

Department of Infectious and tropical diseases, Hôpital Bicêtre, Assistance Publique - Hôpitaux de Paris, Paris-Saclay University, Le Kremlin-Bicêtre, France; QE-Le Moulon, INRA-Université Paris-Saclay-CNRS-AgroParisTech, 91400 Orsay, France.

M Labetoulle (M)

Department of Ophthalmology, Hôpital Bicêtre, Assistance Publique - Hôpitaux de Paris, Paris-Saclay University, French Reference network for rare Ophthalmologic diseases (OPHTARA), Le Kremlin-Bicêtre, France; Immunology of viral and autoimmune disease, IMVA, IDMIT, U1184, CEA, Fontenay aux Roses, France.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH